There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXCR4


CXCR4 Molecule Information

Name:C-X-C motif chemokine receptor 4
Target Synonym:C-X-C chemokine receptor type 4;FB22;Leukocyte-derived seven transmembrane domain receptor;SDF-1 receptor;CXC-R4;LAP-3;NPYRL;CXCR-4;LPS-associated protein 3;CD_antigen=CD184;LESTR;CXCR4;Fusin;HM89;Lipopolysaccharide-associated protein 3;LCR1;Stromal cell-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

CXCR4 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CX4-H5269 Human Human CXCR4 / CD184 Protein, Fc Tag

ecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

CXCR4 References

CXCR4 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Plerixafor JM-3100; JKL-169; AMD-3100; SDZ-SID-791,JKL169,AMD 3100,JM3100,JM 3100,JKL 169,AMD3100 Approved Genzyme MOZOBIL fda Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL), Hematopoietic stem cell transplantation (HSCT) GENZYME 2008-12-15 Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL), Hematopoietic stem cell transplantation (HSCT) Details

CXCR4 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PF-06747143 PF-06747143 Phase Ⅰ Pfizer Acute granulocytic leukemia Details
LY-2510924 LY-2510924; T-134 Phase Ⅱ Lilly Small cell lung cancer (SCLC), Renal cell carcinoma Details
Mavorixafor AMD-070; AMD-11070; X4P-001-RD; X4P-001-IO; X4P-001; X4P-001-LD Phase Ⅲ Genzyme, X4 Pharmaceuticals Neutropenia, Clear cell renal cell cancer (ccRCC), Immunodeficiency disorders, Melanoma Details
AD-214 AD-214 Phase Ⅰ AdAlta Interstitial lung disease Details
Anti-CXCR4 monoclonal antibody (Lilly) Phase Ⅰ Lilly Cancer Details
Ulocuplumab BMS-936564; MDX-1338,BMS936564; MDX1338 Phase Ⅱ Bristol-Myers Squibb Small cell lung cancer (SCLC), Multiple myeloma (MM), Acute myeloid Leukemia (AML), Pancreatic cancer Details
ALX-404C 4C; ALX-40; ALX-40-4C; ALX-404C; ALX40-4; ALX40 Phase Ⅱ Shire HIV infection Details
MSX-122 MSX-122; Q-122; WZ-40,MSX122,Q122, WZ40 Phase Ⅱ Altiris Therapeutics Vasomotor symptoms, Hot flushes Details
[68Ga]Pentixafor Phase Ⅰ University of Iowa Neuroendocrine tumors (NET), Diagnostic agents Details
PTX-9908 PTX-9908 Phase Ⅱ Pertinax Therapeutics Liver cancer Details
NRP-2945 NNZ-4945; NRP-2945 Phase Ⅱ Neuren Pharmaceuticals Epilepsy/Seizures Details
Motixafortide 4F-Benzoyl-TN14003; BKT-140; BL-8040; TF-14016; TN-14003 Phase Ⅲ Biokine, BioLineRx Stem cell mobilization Details
ALX-0651 ALX- 0651 Phase Ⅰ Ablynx Cancer Details
CTCE-9908 CTCE-9908 Phase Ⅱ British Canadian BioSciences Solid tumours Details
USL-311 USL-311 Phase Ⅱ Ligand, Upsher Smith Laboratories Solid tumours, Glioblastoma Details
Balixafortide POL-6326 Phase Ⅲ Polyphor Breast cancer Details
Burixafor Hydrobromide TG-0054,TG0054 Phase Ⅱ TaiGen Biotechnology Hematopoietic stem cell transplantation (HSCT) Details
vMIP (Jinan University) Phase Ⅱ Jinan University Unspecified Details
CTCE-0214 CTCE-0214; CT-0214 Phase Ⅰ British Canadian BioSciences Stem cell mobilization Details
LEO-35299 LEO-35299 Phase Ⅰ Leo Pharma Psoriasis Details
GMI-1359 GMI-1359 Phase Ⅰ GlycoMimetics Pharmaceutical Solid tumours Details
90Y-Pentixather Phase Not Specified University of Wurzburg, Technical University of Munich Multiple myeloma (MM) Details
JVS-100 ACRX-100; JVS-100; SRX-100; GP-51801,GP51801 Phase Ⅱ Cleveland Clinic, Juventas Therapeutics, SironRX Therapeutics, Nanjing Gritpharma Peripheral ischaemia, Heart failure, Peripheral arterial disease (PAD) Details
177Lu-Pentixather Phase Not Specified University of Wurzburg, Technical University of Munich Leukemia, Multiple myeloma (MM) Details

This web search service is supported by Google Inc.